Cancer care has become the single largest medical cost driver for employers, accounting for 15–20% of total medical spend, growing faster than any other category. Yet despite this investment, many employees still don't receive high-value, evidence-based cancer care, and employers often lack the data on whether higher spend leads to better outcomes.
Processing Content
MSK Direct can help. We recently published a resource, Measuring Value in Cancer Care, designed specifically for employer benefit leaders.
It explains:
- Why traditional oncology networks fail to differentiate quality
- How survival outcomes can vary by 20–30% depending on where care is delivered
- The two metrics that matter most when evaluating cancer care value
If cancer is a growing concern in your benefits strategy,
View the MSK Direct resource,
